Reduction/elimination of blood eosinophils in severe asthma: should there be a safety consideration?

References

• KF C, Se W, JL B, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. [published correction appears in Eur Respir J. 2014 Apr;43(4):1216.Dosage error in article text] [published correction appears in Eur Respir J. 2018 Jul27;52(1):].
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020 2020 Jan 2;55(1):1900588. Published.
   PubMed Web of Science ®Google Scholar
• McDowell PJ, Heaney LG. Different endotypes and phenotypes drive the heterogeneity in severe asthma. Allergy. 2020;75(2):302–310.
   PubMed Web of Science ®Google Scholar
• Busse WW. Biological treatments for severe asthma: a major advance in asthma care. Allergol Int. 2019;68(2):158–166.
   PubMedGoogle Scholar
• Lee JJ, Jacobsen EA, McGarry MP, et al. Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy. 2010;40(4):563–575. doi:https://doi.org/10.1111/j.1365-2222.2010.03484.x.
   PubMed Web of Science ®Google Scholar
• Eng SS, DeFelice ML, Role T. Immunobiology of Eosinophils in the Respiratory System: a Comprehensive Review. Clin Rev Allergy Immunol. 2016;50(2):140–158.
   PubMed Web of Science ®Google Scholar
• Gleich GJ, Klion AD, Lee JJ, et al. The consequences of not having eosinophils. Allergy Eur J Allergy Clin Immunol. 2013;(7). Published online. https://doi.org/10.1111/all.12169
   Google Scholar
• Ravin KA, Loy M. The Eosinophil in Infection. Clin Rev Allergy Immunol. 2016;50(2):214–227.
   PubMed Web of Science ®Google Scholar
• Bochner BS. The eosinophil: for better or worse, in sickness and in health. Ann Allergy Asthma Immunol. 2018;121(2):150–155.
   PubMed Web of Science ®Google Scholar
• LeMessurier KS, Samarasinghe AE. Eosinophils: nemeses of Pulmonary Pathogens? Curr Allergy Asthma Rep. 2019 2019 Jun 19;19(8):36. Published.
   PubMed Web of Science ®Google Scholar
• Hillas G, Fouka E, Papaioannou AI. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab. Expert Rev Respir Med. 2020;14(4):353–365.
   PubMed Web of Science ®Google Scholar
• Ramirez GA, Yacoub MR, Ripa M, et al. Eosinophils from Physiology to Disease: a Comprehensive Review. Biomed Res Int. Published. 2018;2018:9095275. 2018 Jan 28.
   PubMed Web of Science ®Google Scholar
• Salter BM, Sehmi R. Hematopoietic Processes in Eosinophilic Asthma. Chest. 2017;152(2):410–416.
   PubMed Web of Science ®Google Scholar
• Bhalla A, Mukherjee M, Nair P. Airway Eosinophilopoietic and Autoimmune Mechanisms of Eosinophilia in Severe Asthma. Immunol Allergy Clin North Am. 2018;38(4):639–654.
   PubMed Web of Science ®Google Scholar
• Sehmi R, Smith SG, Kjarsgaard M, et al. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma. Clin Exp Allergy. 2016;46(6):793–802.
   PubMed Web of Science ®Google Scholar
• Punia N, Smith S, Thomson JV, et al. Interleukin-4 and interleukin-13 prime migrational responses of haemopoietic progenitor cells to stromal cell-derived factor-1α. Clin Exp Allergy. 2012;42(2):255–264.
   PubMed Web of Science ®Google Scholar
• Liao W, Long H, Chang CC, et al. The Eosinophil in Health and Disease: from Bench to Bedside and Back. Clin Rev Allergy Immunol. 2016;50(2):125–139.
   PubMed Web of Science ®Google Scholar
• Capron M, Torpier G, Capron A. In vitro killing of S. mansoni schistosomula by eosinophils from infected rats: role of cytophilic antibodies. J Immunol. 1979;123(5):2220–2230.
   PubMed Web of Science ®Google Scholar
• Buys J, Wever R, van Stigt R, et al. The killing of newborn larvae of Trichinella spiralis by eosinophil peroxidase in vitro. Eur J Immunol. 1981;11(10):843–845.
   PubMed Web of Science ®Google Scholar
• Huang L, Appleton JA. Eosinophils in Helminth Infection: defenders and Dupes. Trends Parasitol. 2016;32(10):798–807.
   PubMed Web of Science ®Google Scholar
• Meeusen EN, Balic A. Do eosinophils have a role in the killing of helminth parasites? Parasitol Today. 2000;16(3):95–101.
   PubMedGoogle Scholar
• Linch SN, Gold JA. The role of eosinophils in non-parasitic infections. Endocr Metab Immune Disord Drug Targets. 2011;11(2):165–172.
   PubMedGoogle Scholar
• Malik A, Batra JK. Antimicrobial activity of human eosinophil granule proteins: involvement in host defence against pathogens. Crit Rev Microbiol. 2012;38(2):168–181.
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Lacy P, Ueki S. Eosinophil Extracellular Traps and Inflammatory Pathologies-Untangling the Web! Front Immunol. 2018 2018 Nov 26;9:2763. Published
   PubMed Web of Science ®Google Scholar
• O’Connell EM, Nutman TB. Eosinophilia in Infectious Diseases. Immunol Allergy Clin North Am. 2015;35(3):493–522.
   PubMed Web of Science ®Google Scholar
• Lavoignet CE, Le Borgne P, Chabrier S, et al. White blood cell count and eosinopenia as valuable tools for the diagnosis of bacterial infections in the ED. Eur J Clin Microbiol Infect Dis. 2019;38(8):1523–1532.
   PubMed Web of Science ®Google Scholar
• Flores-Torres AS, Salinas-Carmona MC, Salinas E, et al. Eosinophils and Respiratory Viruses. Viral Immunol. 2019;32(5):198–207.
   PubMedGoogle Scholar
• Sabogal Piñeros YS, Bal SM, Dijkhuis A, et al. Eosinophils capture viruses, a capacity that is defective in asthma. Allergy. 2019;74(10):1898–1909.
   PubMed Web of Science ®Google Scholar
• Simon SCS, Utikal J, Umansky V. Opposing roles of eosinophils in cancer. Cancer Immunol Immunother. 2019 May;68(5):823–833. Epub 2018 Oct 9. PMID: 30302498.
   PubMed Web of Science ®Google Scholar
• Sakkal S, Miller S, Apostolopoulos V, et al. Eosinophils in Cancer: favourable or Unfavourable? PMID: 26785997 Curr Med Chem. 2016;237:650–666.
   PubMed Web of Science ®Google Scholar
• Davis BP, Rothenberg ME. Eosinophils and cancer. Cancer Immunol Res. 2014 Jan 2;(1):1–8. PMID: 24778159. https://doi.org/10.1158/2326-6066.CIR-13-0196
   Google Scholar
• Parulekar AD, Diamant Z, Hanania NA. Role of T2 inflammation biomarkers in severe asthma. Curr Opin Pulm Med. 2016 Jan;22(1):59–68. PMID: 26574724.
   PubMed Web of Science ®Google Scholar
• Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13.
   PubMed Web of Science ®Google Scholar
• Brussino L, Heffler E, Bucca C, et al. Eosinophils Target Therapy for Severe Asthma: critical Points. Biomed Res Int. 2018 2018 Oct 25;2018:7582057. Published
   PubMed Web of Science ®Google Scholar
• Caminati M, Menzella F, Guidolin L, et al. Targeting eosinophils: severe asthma and beyond. Drugs Context. 2019 2019 Jul 23;8:212587. Published
   PubMedGoogle Scholar
• Eger KA, Bel EH. The emergence of new biologics for severe asthma. Curr Opin Pharmacol. 2019;46:108–115.
   PubMed Web of Science ®Google Scholar
• Patel TR, Sur S. IgE and eosinophils as therapeutic targets in asthma. Curr Opin Allergy Clin Immunol. 2017;17(1):42–49.
   PubMed Web of Science ®Google Scholar
• Walsh GM. Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma. Expert Rev Respir Med. 2018;12(11):957–963.
   PubMed Web of Science ®Google Scholar
• Schleich FN, Chevremont A, Paulus V, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J. 2014;44(1):97–108.
   PubMed Web of Science ®Google Scholar
• Kostikas K, Zervas E, Gaga M. Airway and systemic eosinophilia in asthma: does site matter? Eur Respir J. 2014;44(1):14–16.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Calabrese C, Barbuto S, et al. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: results of a 5-YEAR single-centre observational study. Pulm Pharmacol Ther. 2019;54:25–30.
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Kjarsgaard M, Radford K, et al. Omalizumab in patients with severe asthma and persistent sputum eosinophilia. Allergy Asthma Clin Immunol. 2019 2019 Apr 3;15(1):21. Published.
   PubMedGoogle Scholar
• Humbert M, Taillé C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018 2018 May 10;51(5):1702523. Published.
   PubMed Web of Science ®Google Scholar
• Esquivel A, Busse WW, Calatroni A, et al. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. Am J Respir Crit Care Med. 2017;196(8):985–992.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. [published correction appears in N Engl J Med. 2015 Apr 30;372(18):1777].
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. [published correction appears in Lancet Respir Med. 2015 Apr;3(4):e15] [published correction appears in Lancet Respir Med. 2016 Oct;4(10):e50].
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127.
   PubMed Web of Science ®Google Scholar
• Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017 2017 Sep 21;9(9):CD010834. Published.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for Inadequately Controlled Asthma with Elevated Blood Eosinophil Levels: a Randomized Phase 3 Study. Chest. 2016;150(4):789–798.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141.
   PubMed Web of Science ®Google Scholar
• Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086–1096. [published correction appears in J Allergy Clin Immunol. 2014 Apr;133(4):1232]. . ;():. e5.
   PubMed Web of Science ®Google Scholar
• Caminati M, Bagnasco D, Vaia R, et al. New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic. Biologics. 2019 2019 May 22;13:89–95. Published
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab. Am J Respir Crit Care Med. 2018;197(1):38–46.
   PubMed Web of Science ®Google Scholar
• Kelly EA, Esnault S, Liu LY, et al. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma. Am J Respir Crit Care Med. 2017;196(11):1385–1395.
   PubMed Web of Science ®Google Scholar
• Busse WW, Katial R, Gossage D, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. 2010;125(6):1237–1244.e2.
   PubMed Web of Science ®Google Scholar
• Mesnil C, Raulier S, Paulissen G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016;126(9):3279–3295.
   PubMed Web of Science ®Google Scholar
• Abdala-Valencia H, Me C, Se C, et al. Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease. J Leukoc Biol. 2018;104(1):95–108.
   PubMed Web of Science ®Google Scholar
• Abdala Valencia H, Loffredo LF, Misharin AV, et al. Phenotypic plasticity and targeting of Siglec-F(high) CD11c(low) eosinophils to the airway in a murine model of asthma. Allergy. 2016;71(2):267–271.
   PubMed Web of Science ®Google Scholar
• Jacobsen EA, Helmers RA, Lee JJ, et al. The expanding role(s) of eosinophils in health and disease. Blood. 2012;120(19):3882–3890.
   PubMed Web of Science ®Google Scholar
• Swartz JM, Dyer KD, Cheever AW, et al. Schistosoma mansoni infection in eosinophil lineage-ablated mice. Blood. 2006;108(7):2420–2427.
   PubMed Web of Science ®Google Scholar
• Davoine F, Cao M, Wu Y, et al. Virus-induced eosinophil mediator release requires antigen-presenting and CD4+ T cells. J Allergy Clin Immunol. 2008;122(1):69–77.e772.
   PubMed Web of Science ®Google Scholar
• Peebles, Jr. RS Jr, Hashimoto K, Collins RD, et al. Immune interaction between respiratory syncytial virus infection and allergen sensitization critically depends on timing of challenges. J Infect Dis. 2001;184(11):1374–1379.
   PubMed Web of Science ®Google Scholar
• Phipps S, Lam CE, Mahalingam S, et al. Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood. 2007;110(5):1578–1586.
   PubMed Web of Science ®Google Scholar
• Samoszuk M. Eosinophils and human cancer. Histol Histopathol. 1997;12(3):807–812.
   PubMed Web of Science ®Google Scholar
• Kung TT, et al. Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody. Am J Respir Cell Mol Biol. 1995;13.3(3):360–365. .
   Web of Science ®Google Scholar
• Mauser PJ, Pitman AM, Fernandez X, et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med. 1995;152(2):467–472.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659.
   PubMed Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742–1751.e7.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. United States Cancer Statistics Review. National Cancer Institute; 1975-2011.
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. United States—SEER Prostate Cancer Statistics. National Cancer Institute; 1975-2011.
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. United States—SEER Breast Cancer Statistics. National Cancer Institute; 1975-2011.
   Google Scholar
• Khurana S, Brusselle GG, Bel EH, et al. Long-term Safety and Clinical Benefit of Mepolizumab in Patients with the Most Severe Eosinophilic Asthma: the COSMEX Study. Clin Ther. 2019;41(10):2041–2056.e5.
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Caminati M, Menzella F, et al. One year of mepolizumab. Efficacy and safety in real-life in Italy. Pulm Pharmacol Ther. 2019;58:101836.
   PubMed Web of Science ®Google Scholar
• Pertzov B, Unterman A, Shtraichman O, et al. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. J Asthma. 2021;58(1):79–84.
   PubMed Web of Science ®Google Scholar
• Murphy K, Jacobs J, Bjermer L, et al. Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2017;5(6):1572–1581.e3. [published correction appears in J Allergy Clin Immunol Pract. 2018 May-Jun;6 (3):1095].
   PubMed Web of Science ®Google Scholar
• EMA. European public assessment report (EPAR): cinqaero_(reslizumab). 2016. http://www.ema.europa.eu. Accessed 28 Mar 2017
   Google Scholar
• Markowitz JE, Jobe L, Miller M, et al. Eke R. Safety and Efficacy of Reslizumab for Children and Adolescents with Eosinophilic Esophagitis Treated for 9 Years. J Pediatr Gastroenterol Nutr. 2018;66(6):893–897.
   PubMed Web of Science ®Google Scholar
• Bourdin A, Shaw D, Menzies-Gow A, et al. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. J Asthma. 2019;1–9. [published online ahead of print, 2019 Dec 26]. https://doi.org/10.1080/02770903.2019.1705333
   Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Bourdin A, et al. Two-Year Integrated Efficacy and Safety Analysis of Benralizumab In Severe Asthma. J Asthma Allergy. Published. 2019;12:401–413. 2019 Dec 9.
   PubMed Web of Science ®Google Scholar
• Liu W, Ma X, Zhou W. Adverse events of benralizumab in moderate to severe eosinophilic asthma: a meta-analysis. Medicine (Baltimore). 2019;98(22):e15868.
   PubMed Web of Science ®Google Scholar
• Zayed Y, Kheiri B, Banifadel M, et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J Asthma. 2019;56(10):1110–1119.
   PubMedGoogle Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486–2496.
   PubMed Web of Science ®Google Scholar